<DOC>
	<DOCNO>NCT01319916</DOCNO>
	<brief_summary>Open Label Study Evaluate Serum Lipid Adipokine Profiles Following Subcutaneous Injection ATX-101 Abdominal Fat Tissue</brief_summary>
	<brief_title>Lipid Adipokine Profiles Following Subcutaneous Injection ATX-101 Into Abdominal Fat Tissue</brief_title>
	<detailed_description>Phase 1 , Open Label Study Evaluate Serum Lipid Adipokine Profiles Following Subcutaneous Injection ATX-101 ( Sodium Deoxycholate Injection ) Abdominal Fat Tissue</detailed_description>
	<criteria>1 . Healthy , nonsmoking male nonpregnant , nonlactating female 18 65 year age , inclusive , Day 1A . 2 . Body mass index ( BMI ) 18.5 ≤ 30.0 within 28 day dose study material . 3 . Stable weight ( e.g. , approximately ± 10 lb ) , judgment investigator , least 3 month Day 1A . 4 . Sufficient abdominal tissue surface 50 injection space 1 cm grid ( 4 cm x 9 cm square ) safely administer fat tissue . 5 . Fasting glucose within normal limit ( i.e. , 75100 mg/dL ) within 28 day dose study material . 6 . Fasting hemoglobin A1c within normal limit laboratory designate trial ( e.g. , 4 5.9 % ) within 28 day dose study material . 7 . Fasting triglyceride within normal limit laboratory designate trial ( e.g. , &lt; 150m/dL ) within 28 day dose study material . 8 . Fasting cholesterol within normal limit laboratory designate trial ( e.g. , &lt; 200 mg/dL ) within 28 day dose study material . 9 . Females must negative serum human chorionic gonadotropin ( hCG ) test result sample obtain within 28 day begin confinement period admission research facility confinement period , dose study material . Females must agree practice adequate contraception , judgment investigator , course trial . 10 . Negative hepatitis B , hepatitis C , HIV test result . 11 . The subject expect comply understand visit schedule protocolspecified test procedure . 12 . The subject medically able undergo administration study material determine clinical laboratory evaluation obtain within 28 day Day 1A investigator identifies clinically significant abnormality . 13 . Signed informed consent obtain studyspecific procedure conduct 1 . History intervention ( e.g. , liposuction ) trauma associate abdominal area , judgment investigator , may affect subject 's safety evaluation treatment . 2 . Subjects , reason , active diet , calorie restriction , attempt lose weight . 3 . Blood donation 500 mL blood transfusion within 60 day Day 1A , plasma donation within 7 day Day 1A . 4 . Diagnosis lipodosis ( e.g. , Gaucher , NiemannPick , Fabry disease ) confound metabolic disease . 5 . History hypertriglyceridemia ( triglyceride &gt; 200 mg/dL ) , hypercholesterolemia ( cholesterol &gt; 240 mg/dL ) , hyperlipidemia . 6 . Use statin ( e.g. , Vitorin , Lipitor , Lopid ) lipidlowering agent ( e.g. , nicotinic acid ) within 28 day five ( 5 ) halflives , whichever great , Day 1A . 7 . History diabetes screen result indicative diabetes . 8 . Use antiglycemic agent time screen . 9 . Use medication result systemic exposure begin screening period . 10 . Any medical condition ( e.g. , respiratory , cardiovascular , renal , hepatic , neurological disease , uncontrolled hypertension , thyroid dysfunction ) would interfere laboratory safety assessment , compromise ability subject undergo study procedure , compromise subject 's ability give inform consent . 11 . Treatment oral anticoagulant ( e.g. , warfarin , heparin ) within 10 day Day 1A ; anticipate need agent anticoagulative effect course trial . 12 . History sensitivity component study material topical anesthetic ( e.g. , lidocaine , benzocaine , novocaine ) . 13 . Previous enrollment trial treatment ATX101 agent contain deoxycholate . 14 . Treatment investigational agent within 28 day Day 1A .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>